RÉSUMÉ
Perineuronal nets (PNN) are highly specialized structures of the extracellular matrix around specific groups of neurons in the central nervous system (CNS). They play functions related to optimizing physiological processes and protection neurons against harmful stimuli. Traditionally, their existence was only described in the CNS. However, there was no description of the presence and composition of PNN in the enteric nervous system (ENS) until now. Thus, our aim was to demonstrate the presence and characterize the components of the PNN in the enteric nervous system. Samples of intestinal tissue from mice and humans were analyzed by RT-PCR and immunofluorescence assays. We used a marker (Wisteria floribunda agglutinin) considered as standard for detecting the presence of PNN in the CNS and antibodies for labeling members of the four main PNN-related protein families in the CNS. Our results demonstrated the presence of components of PNN in the ENS of both species; however its molecular composition is species-specific.
RÉSUMÉ
We originally reported that an ethyl-acetate fraction (EAF) of Trichilia catigua prevented the impairment of water maze learning and hippocampal neurodegeneration after transient global cerebral (TGCI) in mice. We extended that previous study by evaluating whether T. catigua (i) prevents the loss of long-term retrograde memory assessed in the aversive radial maze (AvRM), (ii) confers hippocampal and cortical neuroprotection, and (iii) mitigates oxidative stress and neuroinflammation in rats that are subjected to the four vessel occlusion (4-VO) model of TGCI. In the first experiment, naive rats were trained in the AvRM and then subjected to TGCI. The EAF was administered orally 30min before and 1h after TGCI, and administration continued once per day for 7days post-ischemia. In the second experiment, the EAF was administered 30min before and 1h after TGCI, and protein carbonylation and myeloperoxidase (MPO) activity were assayed 24h and 5days later, respectively. Retrograde memory performance was assessed 8, 15, and 21days post-ischemia. Ischemia caused persistent retrograde amnesia, and this effect was prevented by T. catigua. This memory protection (or preservation) persisted even after the treatment was discontinued, despite the absence of histological neuroprotection. Protein carbonyl group content and MPO activity increased around 43% and 100%, respectively, after TGCI, which were abolished by the EAF of T. catigua. The administration of EAF did not coincide with the days of memory testing. The data indicate that antioxidant and/or antiinflammatory actions in the early phase of ischemia/reperfusion contribute to the long-term antiamnesic effect of T. catigua.
Sujet(s)
Amnésie rétrograde/traitement médicamenteux , Amnésie rétrograde/étiologie , Encéphalopathie ischémique/complications , Inflammation/traitement médicamenteux , Inflammation/étiologie , Meliaceae/composition chimique , Stress oxydatif/effets des médicaments et des substances chimiques , Extraits de plantes/usage thérapeutique , Animaux , Marqueurs biologiques/métabolisme , Cortex cérébral/effets des médicaments et des substances chimiques , Cortex cérébral/métabolisme , Modèles animaux de maladie humaine , Hippocampe/métabolisme , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Extraits de plantes/composition chimique , RatsRÉSUMÉ
A series of our previous studies demonstrated that fish oil (FO), equivalent to 300mg/kg docosahexahenoic acid (DHA), facilitates memory recovery after transient, global cerebral ischemia (TGCI) in the aversive radial maze (AvRM). The present study sought to address two main issues: (i) whether the memory-protective effect of FO that has been observed in the AvRM can be replicated in the passive avoidance test (PAT) and object location test (OLT) and (ii) whether FO at doses that are lower than those used previously can also prevent TGCI-induced memory loss. In Experiment 1, naive rats were trained in the PAT, subjected to TGCI (4-vessel occlusion model), and tested for retrograde memory performance 8 and 15days after ischemia. Fish oil (300mg/kg/day DHA) was given orally for 8days. The first dose was delivered 4h postischemia. In Experiment 2, the rats were subjected to TGCI, treated with the same FO regimen, and then trained and tested in the OLT. In Experiment 3, the rats were trained in the AvRM, subjected to TGCI, administered FO (100, 200, and 300mg/kg DHA), and tested for memory performance up to 3weeks after TGCI. At the end of the behavioral tests, the brains were examined for neurodegeneration and neuroblast proliferation. All of the behavioral tests (PAT, OLT, and AvRM) were sensitive to ischemia, but only the AvRM was able to detect the memory-protective effect of FO. Ischemia-induced neurodegeneration and neuroblast proliferation were unaffected by FO treatment. These results suggest that (i) the beneficial effect of FO on memory recovery after TGCI is task-dependent, (ii) doses of FO<300mg/kg DHA can protect memory function in the radial maze, and (iii) cognitive recovery occurs in the absence of neuronal rescue and/or hippocampal neurogenesis.
Sujet(s)
Huiles de poisson/pharmacologie , Hippocampe/effets des médicaments et des substances chimiques , Accident ischémique transitoire/traitement médicamenteux , Troubles de la mémoire/traitement médicamenteux , Neuroprotecteurs/pharmacologie , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Animaux , Antioxydants/pharmacologie , Apprentissage par évitement/effets des médicaments et des substances chimiques , Apprentissage par évitement/physiologie , Groupe nucléaire basolatéral/effets des médicaments et des substances chimiques , Groupe nucléaire basolatéral/anatomopathologie , Modèles animaux de maladie humaine , Hippocampe/anatomopathologie , Accident ischémique transitoire/complications , Accident ischémique transitoire/anatomopathologie , Accident ischémique transitoire/psychologie , Mâle , Troubles de la mémoire/étiologie , Troubles de la mémoire/anatomopathologie , Maladies neurodégénératives/traitement médicamenteux , Maladies neurodégénératives/étiologie , Maladies neurodégénératives/anatomopathologie , Maladies neurodégénératives/psychologie , Neurogenèse/effets des médicaments et des substances chimiques , Neurones/effets des médicaments et des substances chimiques , Neurones/anatomopathologie , Rat Wistar , Récupération fonctionnelle/physiologie , Mémoire spatiale/effets des médicaments et des substances chimiques , Mémoire spatiale/physiologieRÉSUMÉ
We reported that fish oil (FO) prevented the loss of spatial memory caused by transient, global cerebral ischemia (TGCI), provided the treatment covered the first days prior to and after ischemia. Continuing these studies, trained rats were subjected to TGCI, and FO was administered for 10days, with a time window of efficacy (TWE) of 4, 8 or 12h post-ischemia. Retrograde memory was assessed up to 43days after TGCI. In another experiment, ischemic rats received FO with a 4- or 12-h TWE, and dendritic density was assessed in the hippocampus and cerebral cortex. The brain lipid profile was evaluated in sham-operated and ischemic rats that were treated with FO or vehicle with a 4-h TWE. Ischemia-induced retrograde amnesia was prevented by FO administration that was initiated with either a 4- or 8-h TWE. Fish oil was ineffective after a 12-h TWE. Independent of the TWE, FO did not prevent ischemic neuronal death. In the hippocampus, but not cerebral cortex, TGCI-induced dendritic loss was prevented by FO with a 4-h TWE but not 12-h TWE. The level of docosahexaenoic acid almost doubled in the hippocampus in ischemic, FO-treated rats (4-h TWE). The data indicate that (i) the anti-amnesic effect of FO can be observed with a TWE of up to 8h, (ii) the stimulation of dendritic neuroplasticity may have contributed to this effect, and (iii) DHA in FO may be the main active constituent in FO that mediates the cognitive and neuroplasticity effects on TGCI.
Sujet(s)
Dendrites/effets des médicaments et des substances chimiques , Huiles de poisson/administration et posologie , Hippocampe/effets des médicaments et des substances chimiques , Accident ischémique transitoire/traitement médicamenteux , Mémoire à long terme/effets des médicaments et des substances chimiques , Neuroprotecteurs/administration et posologie , Amnésie rétrograde/traitement médicamenteux , Amnésie rétrograde/étiologie , Amnésie rétrograde/métabolisme , Amnésie rétrograde/anatomopathologie , Animaux , Cortex cérébral/effets des médicaments et des substances chimiques , Cortex cérébral/métabolisme , Cortex cérébral/anatomopathologie , Dendrites/métabolisme , Dendrites/anatomopathologie , Modèles animaux de maladie humaine , Acide docosahexaénoïque/métabolisme , Hippocampe/métabolisme , Hippocampe/anatomopathologie , Accident ischémique transitoire/métabolisme , Accident ischémique transitoire/anatomopathologie , Accident ischémique transitoire/psychologie , Mâle , Mémoire à long terme/physiologie , Maladies neurodégénératives/traitement médicamenteux , Maladies neurodégénératives/métabolisme , Maladies neurodégénératives/anatomopathologie , Maladies neurodégénératives/psychologie , Plasticité neuronale/effets des médicaments et des substances chimiques , Plasticité neuronale/physiologie , Nootropiques/administration et posologie , Rat Wistar , Facteurs tempsRÉSUMÉ
Transient, global cerebral ischemia (TGCI) causes hippocampal/cortical damage and the persistent loss of welltrained, long-term memory (retrograde amnesia). Fish oil (FO), a rich source of omega-3 polyunsaturated fatty acids, abolishes such amnesia in the absence of neurohistological protection. The present study investigated whether FO prevents ischemia-induced oxidative stress and whether such an action contributes to the lasting effect of FO on memory recovery. In a first experiment, FO was administered for 4 days prior to ischemia, and antioxidant status was subsequently measured after 24 h of reperfusion. In another experiment, naive rats were trained in an eight-arm radial maze until they achieved asymptotic performance and then subjected to TGCI. One group of rats received FO as in the first experiment (i.e., 4 days prior to ischemia), whereas another group received FO for 4 days prior to ischemia plus 6 days postischemia. Retrograde memory performance was assessed 2-5 weeks after ischemia. TGCI depleted the level of antioxidant enzymes and increased the amount of protein carbonylation, indicating oxidative damage. Fish oil reversed oxidative damage to control levels. The same treatment that attenuated oxidative stress after 24 h of reperfusion also prevented retrograde amnesia assessed several weeks later. This antiamnesic effect afforded by short preischemia treatment was comparable to 10 days of treatment but not as consistent. These data indicate that an antioxidant action in the hyperacute phase of ischemia/reperfusion may contribute to the long-term, antiamnesic effect of FO.
Sujet(s)
Huiles de poisson/administration et posologie , Accident ischémique transitoire/traitement médicamenteux , Troubles de la mémoire/prévention et contrôle , Neuroprotecteurs/administration et posologie , Stress oxydatif/effets des médicaments et des substances chimiques , Animaux , Encéphale/effets des médicaments et des substances chimiques , Encéphale/physiopathologie , Modèles animaux de maladie humaine , Accident ischémique transitoire/complications , Accident ischémique transitoire/physiopathologie , Mâle , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Apprentissage du labyrinthe/physiologie , Troubles de la mémoire/étiologie , Troubles de la mémoire/physiopathologie , Stress oxydatif/physiologie , Carbonylation des protéines/effets des médicaments et des substances chimiques , Rat Wistar , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Récupération fonctionnelle/physiologie , Mémoire spatiale/effets des médicaments et des substances chimiques , Mémoire spatiale/physiologieRÉSUMÉ
We previously reported that the phosphodiesterase-5 (PDE5) inhibitor sildenafil prevented neurodegeneration but not learning deficits in middle-aged rats that were subjected to the permanent, three-stage, four-vessel occlusion/internal carotid artery (4-VO/ICA) model of chronic cerebral hypoperfusion (CCH). In the present study, we examined whether the PDE3 inhibitor cilostazol alleviates the loss of long-term memory (i.e., retrograde amnesia) caused by CCH. The effect of sildenafil was then compared to cilostazol. Naive rats (12-15 months old) were trained in a non-food-rewarded eight-arm radial maze and subjected to CCH. One week later, retrograde memory was assessed for 5 weeks. Cilostazol (50mg/kg, p.o.) was administered for 42 days or 15 days, beginning approximately 45 min after the first occlusion stage. Sildenafil (3mg/kg, p.o.) was similarly administered for 15 days only. Histological examination was performed after behavioral testing. Chronic cerebral hypoperfusion caused persistent retrograde amnesia, which was reversed by cilostazol after both short-term and long-term treatment. This antiamnesic effect of cilostazol was sustained throughout the experiment, even after discontinuing treatment (15-day treatment group). This effect occurred in the absence of neuronal rescue. Sildenafil failed to prevent CCH-induced retrograde amnesia, but it reduced hippocampal cell death. Extending previous findings from this laboratory, we conclude that sildenafil does not afford memory recovery after CCH, despite its neuroprotective effect. In contrast, cilostazol abolished CCH-induced retrograde amnesia, an effect that may not depend on histological neuroprotection. The present data suggest that cilostazol but not sildenafil represents a potential strategy for the treatment of cognitive sequelae associated with CCH.